The drug development sector is embracing technologies and digital methods that were previously not as widely used due to the COVID-19 global health crisis.
Maria I. Florez
Advertisement
Articles by Maria I. Florez
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pfizer Receives Unsolicited Mini-Tender Offer for 1 Million Shares from Tutanota: Report
3
Gilead Sciences Enters $2.1 Billion Definitive Agreement to Acquire Ouro Medicines
4
Why CMS Is Tightening ASP Reporting and What Manufacturers Must Get Right
5